PCR & NGS Based Diagnostic Testing Market - By Product (Consumables, Equipment, Labware), By End-use (Hospitals and Clinics, Diagnostic Centers, Ambulatory Settings) & Forecast, 2021-2027

PCR & NGS Based Diagnostic Testing Market Size

PCR and NGS Based Diagnostic Testing Market size exceeded USD 21.5 billion in 2020 and is estimated to grow at a CAGR of over -0.2% from 2021 to 2027. Rising importance of PCR & NGS based diagnostic testing in detection of viruses and other infectious diseases will accelerate the market growth.
 

High risk of infection in geriatric population is one of the major factors responsible for the increased number of PCR & NGS based diagnostic testing. Growing usage of next generation sequencing techniques in the pharma and biopharma industry has boosted the sales of the equipment and consumables across the world. Additionally, increasing R&D activities in diagnostics industry in developed economies will creating growth opportunities for the PCR & NGS based diagnostic testing market.
 

PCR & NGS based diagnostic testing, as the name suggests are diagnostic tests based on technologies like polymerase chain reaction, and next generation sequencing. These tests are carried out to detect or confirm a presence of disease and to monitor its progression. PCR & NGS based diagnostic tests also include the use of diagnostic tools and equipment to analyse the samples and get accurate results. The advancement in technology over the years have aided in developing novel tests to determine the new or rare disease conditions.
 

Many companies and institutions are constantly involved in developing the advanced PCR and NGS technologies and improving the existing technologies for better disease diagnosis. The COVID-19 pandemic has impacted the PCR & NGS based diagnostic testing market positively. There has been tremendous rise in the number of PCR based tests for the detection of COVID-19. The demand for detection kits and consumables has surged all across the world. To cater to the demand, top companies like Thermo Fisher Scientific have increased their production for PCR based detection kits, and number of new companies have entered the market to manufacture diagnostic consumables. On the other hand, high cost of PCR & NGS based diagnostic testing can be a major factor hindering the industry growth

PCR & NGS Based Diagnostic Testing Market Trends

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was detected causing COVID-19. It was first originated in Wuhan, China. But soon it spread across the world and was officially declared as pandemic. The effect of COVID-19 is immensely catastrophic and pushing the healthcare system of even the developed markets such as the U.S. and Italy to the brink of collapse. Detection kits are considered as one of the key factors for tackling the spread of COVID-19 across the globe. Various research institutes and universities are adopting advanced technologies to develop advance testing kits. Medical device manufacturers have surged the development and production of COVID-19 detection kits, thus fostering the PCR & NGS based diagnostic testing market expansion.
 

Several companies are using their technologies and racing against time to develop PCR & NGS based diagnostic testing kits for faster detection of COVID-19 cases. GenMarkDx used its eSensor technology to minimize the risk of sample contamination. Recently, the company received Emergency Use Authorization (EUA) from FDA for its novel coronavirus diagnostic test ePlex SARS-CoV-2. XCR Diagnostics, a U.S. based startup offered their patented technology Xtreme Chain Reaction in point of care solutions. The increased importance of PCR & NGS based diagnostic testing and its high usage for virus detection during the pandemic will impel the PCR and NGS based diagnostic testing market demand.
 

PCR & NGS Based Diagnostic Testing Market Analysis

The consumables segment in the PCR & NGS based diagnostic testing market accounted for USD 18.8 billion in 2020. Consumable segment includes the disposable products that are used in the PCR & NGS based diagnostic testing. This includes diagnostic kits (inclusive of COVID-19 detection kits), reagents, tips, plates, plastic cases etc. As these products are non-reusable, there is repetitive requirement of consumables in diagnostic tests. High demand and usage of consumables products is the prominent reason for its high industry size.
 

The diagnostic centers segment captured 36% of the PCR & NGS based diagnostic testing market share in 2020. The diagnostic centers are the special facilities with extensive variety of diagnostic testing procedures including PCR & NGS based diagnostic testing. Besides, the diagnostic centers have high testing capacity along with high accuracy due to advanced technology and apt medical infrastructure. All these factors are driving the segment growth for diagnostic centers in the short term. However, with reduction in COVID cases and tests, the market is expected to show negative growth by the end of the forecast period.
 

The U.S. dominated the North America PCR & NGS based diagnostic testing market and accounted for over USD 5.4 billion in 2020. Also, the North America market is projected to showcase 1.2% growth rate through 2027 owing to the rising sales of consumables such as test kits, sample collectors and equipment like thermal cyclers. There has been sudden rise in the number of diagnostic tests since the outbreak of a pandemic. Moreover, increase in the diagnostic centers, ambulatory settings and makeshift facilities during the pandemic has resulted in high demand for PCR & NGS based diagnostic testing equipment and consumable materials supporting the industry expansion. In addition, presence of major market players such as Qiagen, Agilent, and Thermo Fisher Scientific among others is aiding the growth of PCR and NGS based diagnostic testing market in the region.
 

PCR & NGS Based Diagnostic Testing Market Share

Some of the key companies functioning in the PCR & NGS based diagnostic testing market include

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Eppendorf AG
• Fluotics
• Hamilton Company
• Illumina, Inc.
• Integra LifeScience Holdings Corporation
• MGI Tech Co., Ltd
• Mascon, Inc.
• Qiagen Inc
• Roche Diagnostics
• Thermo Fisher Scientific
• Thomas Scientific (The Carlyle Group)
• VWR International (Avantor, Inc.)

These industry leaders have been undergoing strategic developments to sustain the market competition and capture sizable revenue share in the testing industry.
 

Some of the recent industry developments:

• In April 2021, Illumina and Kartos Therapeutics announced a partnership to develop an NGS-based TP53 companion diagnostic. This partnership is aimed at expanding the diagnostic offerings in oncology.
   
• In March 2020, Qiagen released QIAstat-Dx test kit to the United States as a first syndromic test for detection of SARS-CoV-2 coronavirus. This novel panel contains assays targeting two genes used to widely detect SARS-CoV-2. This strategy will enhance the overall revenue and brand image of the firm in the industry
   

The PCR & NGS based diagnostic testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Click here to Buy Section of this Report

Market, By Product, 2016-2027 (USD Million)

• Consumables
• Equipment
• Labware

Market, By End-use, 2016-2027 (USD Million)

• Hospital and clinics
• Diagnostic centers
• Ambulatory settings
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
• Asia Pacific
  • India
  • China
  • Japan
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • Saudi Arabia
  • South Africa